Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.
Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC. Ton NC, et al. Among authors: lawrance j. Clin Cancer Res. 2007 Dec 1;13(23):7113-8. doi: 10.1158/1078-0432.CCR-07-1550. Clin Cancer Res. 2007. PMID: 18056191 Clinical Trial.
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-Péotti K, Rolfe L, Jackson A. Jayson GC, et al. Among authors: lawrance j. J Clin Oncol. 2005 Feb 10;23(5):973-81. doi: 10.1200/JCO.2005.01.032. Epub 2004 Oct 4. J Clin Oncol. 2005. PMID: 15466784 Clinical Trial.
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. Mullamitha SA, et al. Among authors: lawrance j. Clin Cancer Res. 2007 Apr 1;13(7):2128-35. doi: 10.1158/1078-0432.CCR-06-2779. Clin Cancer Res. 2007. PMID: 17404096 Clinical Trial.
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC). Jayson GC, et al. Among authors: lawrance j. Eur J Cancer. 2005 Mar;41(4):555-63. doi: 10.1016/j.ejca.2004.11.021. Epub 2005 Jan 22. Eur J Cancer. 2005. PMID: 15737560 Clinical Trial.
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group. Jayson GC, et al. Among authors: lawrance j. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93. doi: 10.1093/jnci/94.19.1484. J Natl Cancer Inst. 2002. PMID: 12359857 Clinical Trial.
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, Deakin DP, Carrington BM, Lawrance JA, Vinnicombe S, Mather SJ, Clayton J, Foley R, Jan H, Kroll S, Harris M, Amess J, Norton AJ, Lister TA, Radford JA. Davies AJ, et al. Among authors: lawrance ja. J Clin Oncol. 2004 Apr 15;22(8):1469-79. doi: 10.1200/JCO.2004.06.055. J Clin Oncol. 2004. PMID: 15084620 Clinical Trial.
33 results